Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition containing renin inhibitor, diuretic agent and folic acid and application thereof

A technology of renin inhibitor and composition, which is applied to the pharmaceutical composition containing renin inhibitor, diuretic and folic acid and its application field, can solve the problem of unknown efficacy, side effects and low bioavailability of aliskiren/hydrochlorothiazide, etc. To achieve the effect of reducing the risk of cardiovascular and cerebrovascular events, taking medicines easily, and reducing medical costs

Inactive Publication Date: 2009-12-02
北京奥萨医药研究中心有限公司 +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage of renin inhibitors is low bioavailability
But so far, the efficacy of the aliskiren / hydrochlorothiazide compound drug on target organs and the side effects of long-term use are unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing renin inhibitor, diuretic agent and folic acid and application thereof
  • Pharmaceutical composition containing renin inhibitor, diuretic agent and folic acid and application thereof
  • Pharmaceutical composition containing renin inhibitor, diuretic agent and folic acid and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1: Protective effect of Aliskiren + indapamide + folic acid on reducing blood pressure and target organ damage in spontaneously hypertensive rats

[0043] SHR rats, weighing 150-180g, were divided into 6 groups on average, 20 rats in each group, including model group, aliskiren (15mg / kg) group, indapamide (0.25mg / kg) group, aliskiren +Indapamide (15+0.25mg / kg) group, Aliskiren+Folic acid (15+0.04mg / kg) group, Aliskiren+Indapamide+Folic acid (15+0.25+0.04mg / kg) group, and another 20 normal rats were taken as the normal control group. Give the same volume of 0.5% CMC solution, weigh once a week, adjust the dosage according to the body weight, and administer the medicine continuously for 20 weeks.

[0044] Detection Indicator:

[0045] (1) Measure the systolic blood pressure of rat tails at different times before administration and after administration, and compare the differences in blood pressure among the groups.

[0046] (2) Urine was collected, urine protei...

Embodiment 2

[0068] Example 2: Protective effect of aliskiren + indapamide + folic acid on target organ damage in stroke-susceptible spontaneously hypertensive rats

[0069] A total of 80 male SHR-SP rats aged about 8 weeks were divided into model group, aliskiren+indapamide+folic acid (30+0.25+0.08mg / kg) group, aliskiren+folic acid group according to blood pressure value. (30+0.08mg / kg) group, Aliskiren (30mg / kg) group. Breeding conditions: room temperature 22±2°C; relative humidity 50%; solid feed and litter were provided by the Experimental Animal Breeding Farm of the Chinese Academy of Medical Sciences; drinking water was pure water. Another WKY control group was set up, with 20 rats in each group. Oral administration, once a day, weighed once a week, adjust the dose according to body weight, for 8 consecutive weeks.

[0070] Observation indicators:

[0071] (1) The diet, survival and behavior of the animals were observed daily, and the occurrence of cerebral apoplexy in each group ...

Embodiment 3

[0092] Example 3: Antihypertensive and target organ protection effects of teragiren + spironolactone + folic acid on hypertensive rats with two kidneys and one clip

[0093] Rats successfully modeled with two kidneys and one clip were divided into 6 groups on average, 20 in each group. + spironolactone (30+2.5mg / kg) group, teragiren + folic acid (30+0.04mg / kg) group, teragiren (30mg / kg) group, spironolactone (2.5mg / kg) group, another 20 normal rats were used as normal control group. Give the same volume of 0.5% CMC solution, weigh once a week, adjust the dosage according to the body weight, and administer the medicine continuously for 20 weeks.

[0094] Detection Indicator:

[0095] (1) Measure the systolic blood pressure of rat tails at different times before administration and after administration, and compare the differences in blood pressure among the groups.

[0096] (2) Collect urine, use turbidimetry to measure urine protein, radioimmunoassay to measure 24h urine α1 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition containing renin inhibitor, diuretic agent and folic acid. The pharmaceutical composition comprises renin inhibitor, diuretic agent and folic-acid-like compound of officinal dosage and a carrier acceptable in terms of pharmacy. The invention also relates to the application of the pharmaceutical composition in preparing medicines for preventing, treating or retarding high blood pressure and target organ damage caused by high blood pressure; in addition, the invention further relates to the application of the pharmaceutical composition in preparing medicines for lowering risk of cardiovascular and cerebrovascular events caused by high blood pressure. The invention belongs to the pharmaceutical field. With the implementation of the invention, the pharmaceutical composition with special usage, provided to the patients, can improve the compliance of the patients, bring convenience to the patients to take medicines and reduce medical expenses, thus enjoying good market prospect.

Description

technical field [0001] The present invention relates to a pharmaceutical composition containing a renin inhibitor, a diuretic and folic acid, and the use of the pharmaceutical composition in the preparation of medicines for preventing, treating or delaying hypertension and target organ damage caused by hypertension, The present invention also relates to the use of the pharmaceutical composition in the preparation of medicines for reducing the risk of cardiovascular and cerebrovascular events caused by high blood pressure. belongs to the field of pharmacy. Background technique [0002] As one of the common diseases that endanger people's health, essential hypertension is the main cause of serious cardiovascular and cerebrovascular diseases such as myocardial infarction, stroke, and kidney disease. The main purpose of treating hypertension is to minimize the total risk of death and disability from cardiovascular disease. Lowering blood pressure with drugs can effectively redu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/519A61K31/549A61K31/58A61K9/16A61K9/20A61K9/48A61P9/00A61P9/10A61P9/12A61P13/12A61K31/165A61K31/404A61K31/5375
Inventor 陈明侠王文艳陈光亮徐希平
Owner 北京奥萨医药研究中心有限公司